Targets and Emerging Therapies for Schizophrenia

Overview

New and emerging directions in pharmaceutical research to better treat schizophrenia

Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical research for drug targeting and ...

See more details below
Other sellers (Hardcover)
  • All (6) from $143.31   
  • New (5) from $143.31   
  • Used (1) from $150.58   
Targets and Emerging Therapies for Schizophrenia

Available on NOOK devices and apps  
  • NOOK Devices
  • NOOK HD/HD+ Tablet
  • NOOK
  • NOOK Color
  • NOOK Tablet
  • Tablet/Phone
  • NOOK for Windows 8 Tablet
  • NOOK for iOS
  • NOOK for Android
  • NOOK Kids for iPad
  • PC/Mac
  • NOOK for Windows 8
  • NOOK for PC
  • NOOK for Mac
  • NOOK Study
  • NOOK for Web

Want a NOOK? Explore Now

NOOK Book (eBook)
$103.49
BN.com price
(Save 42%)$181.00 List Price

Overview

New and emerging directions in pharmaceutical research to better treat schizophrenia

Although the dopamine hypothesis has been the cornerstone of schizophrenia therapeutics, it is clear that dopamine-based approaches do not treat all aspects of the disease. Moreover, many schizophrenia patients fail to respond to current antipsychotics. Integrating chemistry, biology, and pharmacology, this book explores emerging directions in pharmaceutical research for drug targeting and discovery in order to find more effective treatments for schizophrenia, one of the most serious and widespread psychiatric diseases.

Targets and Emerging Therapies for Schizophrenia presents the basics of schizophrenia, drug targets for the disease, and potential new drugs and therapeutics. It begins with a discussion of prevalence and etiology. Then, it describes therapies such as dopamine agonists and phosphodiesterase (PDE) inhibitors as well as growing research aimed at addressing untreated symptoms. Next, the authors discuss receptor modulators, inhibitors, and targeting strategies for drug discovery. Both the neurobiological and chemical aspects of all major pharmacological targets are examined.

With contributions from an international team of pioneering pharmaceutical researchers, this book compiles the current knowledge in the field, setting the stage for new breakthroughs in the treatment of schizophrenia. Targets and Emerging Therapies for Schizophrenia:

  • Provides a comprehensive resource for neuro-drug discovery and the development of molecular targets for schizophrenia treatment
  • Draws from chemistry, biology, and pharmacology for more effective drug targeting and discovery
  • Explores a wide range of receptors and molecular targets, including dopamine, PDEs, and neuropeptides

With Targets and Emerging Therapies for Schizophrenia as their guide, drug discovery and development scientists have the information they need to advance their own research so that new, more effective treatments for schizophrenia will soon be a reality.

Read More Show Less

Editorial Reviews

From The Critics
Reviewer: Michael Joel Schrift, D.O., M.A.(University of Illinois at Chicago College of Medicine)
Description: It continues to be unfortunate that schizophrenia is studied as if it is a single disease. The current concept of schizophrenia is likely to include multiple phenotypically overlapping syndromes and diseases, and schizophrenia can no longer be considered a unitary entity. Any research that does not take this heterogeneity seriously has, in my opinion, outlived its usefulness. This book does not, for the most part, incorporate any issues of validity and heterogeneity and most of the chapters use the unitary concept as a default. The book is written and edited largely (but not entirely) by pharmaceutical industry scientists. Although the review of receptor pharmacology is helpful, I did not find that this book, as a whole, advanced my knowledge of psychosis in general and schizophrenia specifically.
Purpose: The purpose, according to the editors, is to "present the basics of schizophrenia, drug targets for the disease, and potential new drugs and therapeutics."
Audience: The intended audience, although not specifically stated, includes psychiatrists, psychiatric researchers, and psychopharmacological researchers.
Features: The chapters cover etiology and prevalence, dopamine agonists and phosphodiesterase inhibitors, receptor modulators, inhibitors, and targeting strategies for drug discovery. Each chapter ends with relevant citations of the scientific literature. The index is quite detailed.
Assessment: Because the book is authored by research scientists working in the pharmaceutical industry, I doubt clinicians would find it useful. I am sorry, but I cannot recommend it.
Read More Show Less

Product Details

  • ISBN-13: 9780470322826
  • Publisher: Wiley, John & Sons, Incorporated
  • Publication date: 7/10/2012
  • Edition number: 1
  • Pages: 494
  • Product dimensions: 6.30 (w) x 9.30 (h) x 1.00 (d)

Meet the Author

JEFFREY S. ALBERT, PhD, is a Project Leader and Head of Lead Generation Chemistry in AstraZeneca's neuroscience department. He has authored or coauthored more than forty publications, mostly focusing on novel therapeutic targets involved in depression, schizophrenia, and Alzheimer's disease and on the development and application of fragment-based lead generation methodologies.

MICHAEL W. WOOD, PhD, is an External Collaborations Director in AstraZeneca's neuroscience unit where he is responsible for coordinating research to deliver novel therapeutics targeting schizophrenia as well as other neuroscience treatments. He has been focused on neuroscience drug discovery research for fifteen years.

Read More Show Less

Table of Contents

Preface

Contributors

Introduction

Alan J. Cross

Chapter 1. Dopaminergic Hypothesis of Schizophrenia: A historical perspective
Aurelija Jucaite, and Svante Nyberg

Chapter 2. Dopamine D2/D3 Partial Agonists as Antipsychotics
Philip G. Strange

Chapter 3. D1/D5 Dopamine Agonists as Pharmacotherapy for Schizophrenia
Kevin N. Boyd, and Richard B. Mailman

Chapter 4. PDE Inhibitors as a Novel Therapeutic Approach for Schizophrenia
Judith A. Siuciak, and William J. Pitts

Chapter 5. Glutamatergic Synaptic Dysregulation in Schizophrenia
Joseph T. Coyle, Alo Basu, and Michael Benneyworth

Chapter 6. Metabotropic Glutamate 2/3 Receptor Agonists and Positive Allosteric Modulators of Metabotropic Glutamate Receptor 2 as Novel Agents for the Treatment of Schizophrenia
Gerard J. Marek, Bruce J. Kinon, David L. McKinzie, Jeffrey M. Schkeryantz, and James A. Monn

  Chapter 7. AMPA Receptor Positive Modulators
John A. Morrow, John K. F. Maclean, and Craig Jamieson

Chapter 8. Progress in the exploration and development of GlyT1 inhibitors for schizophrenia
Jeffrey S. Albert, and Michael W. Wood

Chapter 9. Combined Dopamine D2 and 5-Hydroxytryptamine (5-HT)1A Receptor Strategies for the Treatment of Schizophrenia, a Pharmacological and Chemical Perspective
Andrew C. McCreary, Roelof W. Feenstra, and Caitlin A. Jones

Chapter 10. 5-HT2C and 5-HT6 Receptor Targeted Emerging Approaches in Schizophrenia
Sharon Rosenzweig-Lipson, John Dunlop, Lee E. Schechter, Thomas A. Comery and Karen L. Marquis

Chapter 11. The Cholinergic Hypothesis: an introduction to the hypothesis and a short history
Joseph I. Friedman, Isabella Kanellopoulou, and Vladan Novakovic

Chapter 12. α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia
Mihály Hajós, Pharm, and Bruce N. Rogers

Chapter 13. Muscarinic Acetylcholine Receptors as Novel Targets for the Development of Therapeutics for Schizophrenia
Christian C. Felder, David L. McKinzie, Richard C. Thompson, and Bin Liu

Chapter 14. Will Modulation of Neuropeptide Receptors Produce the Next Generation of Antipsychotic Drugs?: a Focus on the Neurokinin and Neurotensin Systems
Lee A. Dawson, Paul W. Smith, and Jeannette M. Watson

Chapter 15. GABA and Schizophrenia
John  H. Kehne, and George D. Maynard

Index 

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)